Peregrine Pharma (PPHM) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-11.06M
Share-based compensation	837K
Depreciation and amortization
Amortization of discount on notes payable and debt issuance costs
Amortization of expenses paid in shares of common stock
Trade and other receivables, net	-4.68M
Government contract receivables
Inventories, net	-9.09M
Prepaid expenses and other current assets, net	116K
Other non-current assets	78K
Accounts payable	222K
Accrued clinical trial and related fees	-1.02M
Accrued payroll and related expenses	-2.17M
Deferred revenue	11.5M
Deferred government contract revenue
Customer deposits	-2.48M
Other current liabilities	-819K
Other long-term liabilities
Net cash used in operating activities
Property acquisitions
Decrease in other assets
Net cash used in investing activities
Proceeds from issuance of common stock, net of issuance costs of $126,000 and $162,000, respectively	2.12M
Principal payments on notes payable and capital leases
Net cash provided by financing activities
NET DECREASE IN CASH AND CASH EQUIVALENTS	-17.22M
CASH AND CASH EQUIVALENTS, beginning of period	61.41M
CASH AND CASH EQUIVALENTS, end of period	44.2M
Property acquired under capital lease
Accounts payable for purchase of property	444K

Entities mentioned with PPHM

View All Entities